334 PATENT ABSTRACTS

4533632 4534906

P R O D U C T I O N O F A C E P H A L O S P O R I N BY

F E R M E N T A T I O N

R E M O V A L O F I M P U R I T I E S F R O M H U M A N L E U K O C Y T E

I N T E R F E R O N P R E P A R A T I O N S

Alan Smith, Peter J Bailey, Ulverston, United Kingdom assigned to Glaxo Group Limited

A process for greatly improving the yields of cephalosporin nucleus produced by fermenta- tion is described. Cephalosporin C-producing microorganisms are fermented in the presence of an acetylesterase enzyme so that cephalosporin C formed is immediately converted into desacetyl cephalosporin C before any non- enzymic degradation occurs. Fermentation to produce desacetyl cephalosporin C enables yield increases of cephalosporin nucleus of about 40% to be realized, and greater increases are possible if the fermentation is extended. The preferred cephalosporin C-producing organism is Ac- remonium chrysogenum, and mutants thereof that are capable of producing esterases in situ. Alternatively, esterases obtained from a variety of other sources may be added or formed in situ, for example from a strain of Rhodosporidium.

4533634

T I S S U E C U L T U R E M E D I U M

Paul D Johnston assigned to Genentech Inc

Disclosed is a method for removing impurities from leukocyte interferon preparations in- volving use of a unique incubation procedure.

4534966

C O M P O S I T I O N F O R T R E A T I N G I N F E C T I O U S D I S E A S E S , G O U T

O R A R T E R I O S C L E R O S I S C O N T A I N I N G H U M A N P E P S I N A N D / O R H U M A N L E U K O C Y T E

P E P S I N - L I K E E N Z Y M E A N D M E T H O D F O R U S I N G S A M E

Haruo Ohnishi, Hiroshi Kosuzume, Yasuo Suzuki, Ei Mochida, Funabashi, Japan assigned to Mochida Pharmaceutical Co Ltd

There are provided a pharmaceutical composi- tion having an effect to control phagocytic func- tion, which comprises a pharmaceutically effective amount of human pepsin and/or a human leukocyte pepsin-like enzyme and a pharmaceutically acceptable carrier, and a therapeutic method using said composition. The pharmaceutical composition is useful for treat- ment of infectious diseases, gout and ar- teriosclerosis.

Reynaldo L Maldonado, Kenneth Rosanoff as- signed to AMF lnc

A growth factor containing serum is disclosed which is derived from natural bovine serum is disclosed which is by precipitating a first solids fraction from natural bovine serum by adding ammonium sulfate to about 25% saturation to give a first solids fraction and a first supernatant; separating the first solids fraction from the first supernatant; precipitating a second solids frac- tions from the first supernatant by adding am- monium sulfate to about 40% saturation to give a second solids fraction and a second super- natant; separating the second solids fraction from the second supernatant; combining the first solids fraction and the second supernatant; and desalinating the first solids fraction and the second supernatant, either before or after com- bination thereof.

4534967

C E L L P R O L I F E R A T I O N I N H I B I T O R A N D M E T H O D O F

P R E P A R A T I O N

Bernard Jacobson, Laurie Raymond assigned to Boston Biomedical Research Institute

An inhibitor of endothelial cell growth is pre- pared by directly liquifying vitreous gel, as for example, forcing vitreous gel through a small orifice so as to directly convert the gel into a li- quid, removing insoluble and suspended material and chromatographically fractionating the liquid and isolating the fractions. An in- hibitor is also prepared by culturing hyalocyte cells in a medium and chromatographically frac- tionating the medium.